Alivus Life Sciences Ltd

NSE: ALIVUS · BSE: 543322 · Pharmaceuticals & Biotechnology · 9 announcements

Share price: ₹1,365.60
Market cap: ₹16,766 Cr
Revenue (annual): ₹2,552 Cr
Net profit (annual): ₹564.5 Cr
P/E (TTM): 27.8×Sector 50.4×
Promoter holding: 74.87%+0.00% QoQ
FII holding: 5.54%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

Announcement type

All Earnings Call 2 Merger & Restructuring 1 Financial Results 1 Annual General Meeting 1

Time

All time Last 1 week Last 1 month Last 2 months Last 3 months Last 6 months Last 1 year

2 announcements with these filters

31 Jul 2026 11:44 IST BSE

Earnings Call

Alivus Life Sciences Earnings Call Transcript: Key Takeaways

Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.

Call: Guides 11% growth

Open call summary → Read the filing ↗

30 Jul 2026 19:04 IST NSE

Earnings Call

Alivus Life Sciences Investor Presentation: Key Takeaways

Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.

Call: Guides 11% growth

Open call summary → Read the filing ↗